Back to Journals

OncoTargets and Therapy


Dr Farassati

Molecular Medicine, MBRF-STL, United States

Dr Farassati

Editor-in-Chief: Dr Faris Farassati

Dr Faris Farassati is an Associate Professor at the University of Kansas Medical School and the director of the Molecular Medicine Laboratory at this institute. He is a translational cancer scientist focusing on intervention with pro-oncogenic cell signaling machinery in order to treat human malignancies. Therapeutic targets which are identified to be "Cancer-Specific" will be pursued by both gene and drug therapy methods by Dr Farassati's team towards designing a comprehensive translational strategy. Transcriptional targeting of Oncolytic Viruses is a major focus of research for Dr Farassati's group. Ras signaling pathway, as the most important pro-oncogenic signaling pathway involved in generation of human cancers, has been defined as a target for a mutant versions of Herpes Simplex Virus-1(HSV-1). This Ras-Smart virus is named as "Signal-Smart 1" or SS1 virus. Other versions of Oncolytic Viruses developed in this lab include HSV-1 mutants capable of targeting Cancer Stem Cells (CSCs) in a cell-specific manner. These viruses are being developed with the purpose of eliminating CSCs as the main fraction of cells within tumors in charge of repopulating tumors and maintaining different cell types which compose the histological structure of the tumor. Since no therapies currently exist to specifically target CSCs, development of Oncolytic Viruses with such ability can deliver significant potentials for highly effective cancer therapy.


Dr Aoki

Respiratory Division, Department of Internal Medicine, Tokai University School of Medicine, Japan

Dr Aoki

Associate Editor: Takuya Aoki

Dr. Takuya Aoki, M.D., Ph.D. (Ph.D.-internal medicine), is an Associate Professor of Respiratory Division, Department of Internal Medicine, Tokai University School of Medicine. He is a member of the International Association for the Study of Lung Cancer (IASLC), the American Society of Clinical Oncology (ASCO), and the American Thoracic Society (ATS), and also in Japan, Japanese Respiratory Society, West Japan Oncology Group (WJOG), Japanese Society of Internal Medicine, Japan Lung Cancer Society, Japanese Society of Medical Oncology, and Japan Society for Respiratory Endoscopy. His board certified specialities are Japanese Board of Cancer Therapy, Board of Japanese Respiratory Society, and Board of Japanese Society of Internal Medicine. He graduated from Keio University School of Medicine (Tokyo) in 1989, and got Medical Degree. In 1997, he got his Doctor of Philosophy from Keio University Postgraduate School of Medicine, Internal Medicine. Currently Dr. Takuya Aoki’s researches focus on the characteristics of complete remission cases in advanced non-small cell lung cancer. Dr. Aoki has published over 50 peer-reviewed international journals covering many fields of respiratory medicine including lung cancer.


Dr Chhabra

Department of Medicine, University of Connecticut Health Center, United States

Dr Chhabra

Associate Editor: Dr Arvind Chhabra

Dr. Chhabra received his PhD degree from the Central Drug Research Institute  (CDRI), a premier research institute in India, in 2001. He is working as an Assistant Professor in the Department of Medicine, University of Connecticut Health Center, Farmington, Connecticut, since 2008. Dr. Chhabra is working in the area of human cancer immunology and immunotherapy.

Since most human tumor antigens identified are "self-antigens", generation of a potent anti-tumor immune response faces many inherent constraints. Among these constraints include, an extremely low precursor frequency of anti-tumor T cells in most cancer patients and host immune regulatory mechanisms blocking generating of protective anti-tumor immunity. CD4 T cell mediated "help" can facilitate the generation of a productive antigen specific CD8+ cytolytic T lymphocyte (CTL) response, however, engaging CD4 T cells in tumor immunity is quite challenging, especially in an antigen specific manner, as most human tumor are MHC class I positive but MHC class II negative. Dr. Chhabra has developed several innovative approaches to overcome these limitations, utilizing the  human melanoma as a model. Among these approaches include, generation of immunogenic DC by silencing inhibitory molecules, such as IL-10; utilization of "self-translocatable" carrier protein, HSV-VP22, for simultaneous generation of CD4 and CD8 T cell responses; and the creation of donor specific customized MHC class I restricted anti-tumor CD8+ CTL and CD4+ "multifunctional" T cells by engineering human peripheral blood derived T  cells with a MHC class I restricted transgenic T cell receptor (TCR), isolated from melanoma patient derived CD8+ CTL. Dr. Chhabra has also characterized a cell intrinsic, caspase-independent, mitochondria-centric cell death pathway involved in activation induced cell death (AICD)  of human primary anti-tumor T cells, with an objective to generate anti-tumor T cells that can withstand premature AICD and sustain longer in the physiology to produce better clinical outcomes. Dr. Chhabra has published his findings in more than 20 research manuscripts in prominent peer reviewed journals. His work has earned him several awards and honors at national and international cancer immunotherapy platforms. 

In addition to his work on human melanoma model, Dr. Chhabra is also working on extending his TCR engineering expertise to human breast cancer. He is also working on utilizing the human pluripotent stem cells [hPS, i.e. human embryonic stem cells (hES) and induced pluripotent stem cells (iPS)] for generating patient specific "naive" immune effectors, with an objective to develop an effective patient specific personalized cancer immunotherapy approach.


Dr Cho

Queen Elizabeth Hospital, Hong Kong

Dr Cho

Associate Editor: Dr William Cho

Dr William Cho is a Biomedical Scientist in Queen Elizabeth Hospital, Hong Kong. His main research interests have been focused on cancer studies utilizing high-throughput technologies to discover biomarkers for cancer diagnosis, treatment prediction and prognostication. He is a Chartered Scientist granted by the Science Council (UK), a Registered Chinese Medicine Practitioner (HK), a Fellow Member of several institutes, including the Institute of Biomedical Science (UK), Hong Kong Institute of Biomedical Science and Hong Kong Society for Molecular Diagnostic Sciences. Dr Cho has published over 200 peer-reviewed papers covering cancer biomarkers, proteomics, microRNAs and Chinese medicine.

 


Dr Dai

Radiation Oncology, University of FLorida, United States

Dr Dai

Associate Editor: Dr Yao Dai

Dr. Dai obtained his Ph.D degree in Peking Union Medical College in China. He is now an Assistant Professor in Department of Radiation Oncology at University of Florida. Dr. Dai has been working in the field of cancer biology, radiation therapy and experimental therapeutics for over 15 years. His research involves understanding cancer progression and evaluating therapeutic effects of novel molecular targeting agents. Specifically, his original contributions have been made in three major inter-related areas: i) Studying the impact of hypoxia on cancer metastasis; ii) Evaluating anti-cancer activities of novel molecular agents and natural compounds, and iii) Enhancing treatment efficacies by combination therapy. Dr. Dai’s major focus is prostate cancer, while also covering other cancer types such as lung cancer, breast cancer and colorectal cancer, all of which are life-threatening. The ultimate goal of Dr. Dai’s research is to develop effective therapeutic strategies that can be used to benefit cancer patients. Dr. Dai has accomplished many publications, including research articles, reviews, book chapters and patents. He also serves as an ad hoc reviewer for over 20 international journals in biomedical science.


Dr Perche

Dr Perche

Associate Editor: Federico Perche

During his PhD at the Centre for Molecular Biophysics (CBM, Orléans, France) with Dr. Midoux and Dr. Pichon, Federico Perche developed dendritic cell-targeted lipopolyplexes, achieving efficient transfection of splenic dendritic cells in vivo resulting in superior protection against melanoma growth over untargeted mRNA lipopolyplexes. Next, he did a first postdoctoral stay with Pr. Torchilin at the Center for Pharmaceutical Biotechnology and Nanomedicine (Northeastern University, Boston, USA). There he worked on stimuli-sensitive delivery systems for siRNA and drug (paclitaxel and doxorubicin) delivery. With his colleagues, they demonstrated triggered exposure of internalization motifs by two tumor environment stimuli: matrix metalloproteases, and hypoxia. He continued his training in Pharmaceutical Sciences by a second postdoctoral stay as Japanese Society for the Promotion of Science fellow with Pr. Kataoka and Dr Miyata at the Center for Nano Bio Integration (The University of Tokyo, Japan) where he worked on intrathecal delivery of an mRNA coding an anti-Aβ scFv for Alzheimer’s disease immunotherapy and on chloroquine conjugation to gold nanoparticles for improved siRNA activity. 
He secured a permanent Researcher position at the CBM in 2016. His work focuses on intracellular delivery of RNA for anticancer vaccination and for bone regeneration. Using a reductionist approach combining molecular biology and drug delivery, he aims at mimicking RNA viruses’ mechanisms to improve the intracellular bioavailability of transfected RNA for improved activity.


Prof. Dr. Pietersz

Prof. Dr. Pietersz

Associate Editor: Geoffrey Pietersz

Prof Pietersz is a Professor and Principal Research Fellow at the Baker Institute Melbourne, Australia. He obtained his BSc (Hons) and PhD at the University of Melbourne in synthetic organic chemistry in the area of natural products. With a keen interest in working at the interface of biology and organic chemistry he did his postdoctoral work at the Research Centre for cancer and Transplantation (RCCT) at the Melbourne University on drug, toxin, isotope-monoclonal antibody conjugates. During this period he developed many novel immunoconjugates of a number of anti-cancer drugs.
 
In 1991 the RCCT became the Austin Research Institute affiliated with the Austin & Repatriation Medical Centre, Heidelberg. Prof Pietersz developed a vaccine delivery system based on bio-conjugation of tumour associated antigen, mucin 1 to the mannose carbohydrate, mannan which targets antigen presenting cells. Successful efficacy studies in animal models led to several clinical trials in cancer and eventually licensing the IP to Prima Biomed Ltd and Ascend Biopharma Ltd. The antigen-mannan conjugates were also able to prime mucosal and systemic responses when administered via the intranasal route and demonstrated for influenza, RSV and rotavirus. Professor Pietersz also designed several small chemical entities using structure-based design that inhibit immune complexes binding to the FcγRIIa receptor for inflammation.

In 2006 the Austin Research Institute merged with the Burnet Institute and he was appointed the Head of the Bio-organic & Medicinal Chemistry Laboratory until 2016 and now a Honourary Research Fellow. His current research is still focussed on applying bio-conjugation strategies to solve biological problems in inflammation, drug delivery and vaccine delivery and application in translational research. He has 176 peer-reviewed publications and many granted patents in the areas of cancer, inflammation and infectious diseases. He is the Chief Technology officer at Ascend Biopharma Ltd and on the scientific advisory board of Avipep Pty Ltd. Prof Pietersz holds professorial appointments at Melbourne University, Monash University and Victoria University.


Dr Romano

Biology, Temple University, United States

Dr Romano

Associate Editor: Dr. Gaetano Romano

Dr. Gaetano Romano is an Associate Professor in the Department of Biology at Temple University in Philadelphia, Pennsylvania, U.S.A. In the course of his academic activities, Dr. Romano has been conducting several research projects in the fields of tumor immunology, immunogenic cell death, cancer radiation therapy combined with immune checkpoint inhibitors, drug discovery and development in oncological programs, cancer stem cells, mechanisms leading to chemo- and/or radiation resistance in malignant cells, viral and non-viral vectors development for gene therapy, oncolytic viruses, viral oncology, detection of tumors markers in solid biopsies and in peripheral blood, isolation and enumeration of circulating tumor cells and/or circulating tumor DNA from the bloodstream and characterization of cell signaling systems in the context of cancer research, neurodegenerative disorders and stem cell biology.


Professor Saif

Northwell Health Cancer Institute, Zucker School of Medicine, United States

Professor Saif

Co-Section Editor - Clinical Oncology: Professor Wasif Saif

Professor M. Wasif Saif has been recognized as an internationally renowned expert and Key Opinion Leader (KOL) in the fields of Gastrointestinal (GI) cancers, Experimental Therapeutics and Pharmacogenetics, an exemplary clinician, and a great teacher/mentor. He is Deputy Physician-in-Chief and Director of Medical Oncology at the Northwell Health Cancer Institute, as well as Professor of Medical Oncology in the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. Up until December 2018, he served as the Professor of Medicine in Tufts Medical School and the Director of the GI Cancers Program and Program Leader of the Experimental Therapeutics Program at the Tufts Cancer Center, Boston. Over the past 18 years, he has been the principal investigator for over 65 prospective cancer clinical trials, including phase I -III studies embedded with innovative translational research components investigating host-, drug-, and/or tumor-based correlative studies. He serves on the editorial board of innumerable peer review journals, serves as a grant reviewer for competitive grants, and delivers lectures at many esteemed institutions as well as major cancer meetings. He has distinguished himself as an eminent scholar by publishing over 570 scientific papers in addition to text book chapters and abstracts/proceedings of meetings, an extremely unique trait of his, and one he considers his hobby.


Prof. Dr. Silvestris

Medical Oncology Unit, National CancerResearch Centre “Giovanni Paolo II”, Bari, Italy, Italy

Prof. Dr. Silvestris

Associate Editor: Nicola Silvestris

Nicola Silvestris graduated cum laude in 1993 from the Catholic University of Rome School of Medicine, Rome, Italy. He received his Ph.D. degree in 1998. Since graduation, he has become involved in studies on translational research in solid tumors. In this area, he is recognized as a national and international expert, as indicated by the numerous participations in meetings and seminars as an invited speaker. From 2011 he has been involved in the elaboration of guidelines of exocrine pancreatic carcinoma for the Italian Association of Medical Oncology. Since 2015, he is a Founding Member of the Italian Group for Diagnosis and Treatment of Biliary Cancer (GICO). Actually, he is Scientific Director of the National Cancer Institute of Bari. He has published more than 180 papers in peer-reviewed journals. He regularly serves as a reviewer for the most important gastroenterology journals and for funding agencies.


Dr Singh

Division of Biological and Life Sciences, Ahmedabad University, India

Dr Singh

Associate Editor:: Sanjay Singh

Dr Singh is currently an Associate Professor at the Division of Biological and Life Sciences, Ahmedabad University, Ahmedabad, India. During his PhD thesis research in Nanobiotechnology at CSIR – National Chemical Laboratory, Pune, India, Dr Singh demonstrated “Safe by Design” approach for the synthesis of biocompatible nanomaterials, particularly the preparation of metallic and magnetic nanoparticles using bio surfactants. As a postdoctoral fellow at the Burnett School of Biomedical Sciences, University of Central Florida, Orlando, USA, he worked with the cerium oxide based antioxidant nanozymes. During his research fellowship at the Department of Pharmacology, College of Medicine, Pennsylvania State University, Hershey in Pennsylvania, he demonstrated the co-encapsulation of multiple anticancer drugs in nanoliposomes for synergistic treatment of melanoma. 

Dr Singh’s research at Ahmedabad University focused on developing novel inorganic nanozymes exhibiting better catalytic activities than corresponding natural enzymes. His research group is also developing strategies to apply these nanozymes in selective identification as well as prevention and treatment of cancer cells. Applications in bio-sensing and approaches to improve the bio-catalytic as well as chemical catalytic activities of the developed nanozymes are some of the other major research thrusts.

Dr Singh’s current research also include the identification of new biological targets for efficient cancer treatment. His research group also works on the preparation of novel nanoliposomal formulations for the efficient delivery of anticancer drugs and tumor suppressor genes (plasmids and siRNAs) to inhibit the proliferation of cancer cells.

Dr Singh is the author or co-author of over 65 international peer reviewed scientific publications, 6 book chapters, and 1 edited book in the area of Nanobiotechnology and Nanomedicines. Dr Singh has been bestowed with several international awards including the prestigious Endeavour Research Fellowship by Government of Australia, Yamagiwa-Yoshida (YY) Memorial international grant award by Union for International Cancer Control (UICC), International Association of Advanced Materials (IAAM) Scientist Medal, and EMBO (European Molecular Biology Organization) fellowship. 

At national and international levels, Dr Singh has served as reviewer of multiple grants and several international peer reviewed journals of nanoscience and nanotechnology area.

 


Dr Srivastava

Mitchell Cancer Institute, University of South Alabama, United States

Dr Srivastava

Associate Editor: Sanjeev Srivastava

Dr. Sanjeev K Srivastava is an Assistant Professor at the University of South Alabama Mitchell Cancer Institute (USAMCI). Dr. Srivastava received his Ph.D. in Human Genetics in 2007, and completed his post-doctoral trainings at the Semmelweis Medical University, Budapest, Hungary and USAMCI. Dr. Srivastava is engaged in a number of research programs that encompass the areas of breast cancer, pancreatic cancer, prostate cancer, ovarian cancer and melanomas, to identify novel deregulated genes and dissect their underlying regulatory pathways and functional significance. He has published more than 45 international peer-reviewed articles, authored 5 book chapters, and has been the recipient of an international patent. He is a recipient of two NIH/NCI-Small Business Innovation Research (SBIR) Phase I funding for advancing cancer health disparity research. He is also a co-Principal investigator on several NIH/NCI (R01) grant.


Dr Su

Hsuang-Ho Hospital, Taiwan

Dr Su

Associate Editor: Dr Leo Jen-Liang Su

Dr. Su graduated from National Taiwan Normal University and obtained his PhD in National Taiwan University in 2004. He completed postdoctoral trainings at Institute of Toxicology, National Taiwan University, Taipei, Taiwan and M.D. Anderson Cancer Center, The University of Texas, Houston, TX, USA. He is currently an investigator of Hsuang-Ho Hospitalin Taiwan. He has published more than 30 original research papers and review articles in peer-reviewed international journals such as The Journal of Clinical Investigation, American Journal of Respiratory and Critical Care Medicine, Hepatology, Proceedings of the National Academy of Sciences of the United States of America, Cancer Research, Oncogene, etc. Recently, the main research interests of Dr. Su’s laboratory include (1) Metabolism dysregulation in cancer metastasis and drug resistance; (2) Function and biosynthesis of non-coding RNA in cancer; (3) Protein post-translational modification in cancer progression. As an expert of cancer biology, Dr. Su has been a reviewer for numerous scientific journals and served as a member of multiple grant review panels.


Dr Teng

Department of Oral Biology and Dx Diagnostics, Georgia Cancer Center, Augusta University, United States

Dr Teng

Associate Editor: Yong Teng

Dr. Teng is an Assistant Professor of the Department of Oral Biology & Diagnostic Sciences at Augusta University, with a joint appointment in the Department of Medical Laboratory, Imaging and Radiologic Sciences, and the Department of Biochemistry & Molecular Biology. He is also a member of Georgia Cancer Center. Dr. Teng has authored more than 100 articles and chapters in reputed journals (e.g. Cancer Research, Journal of Hematology and Oncology, Oncogene) and books (e.g. Springer), producing over 300 cumulative impact factors and over 1,000 citations. He also serves on multiple grant review panels (e.g. CDMRP PCRP, FWF, CSF), national and international committees and editorial boards (e.g. Journal of Experimental and Clinical Cancer Research, Frontiers in Oncology, Cancer Management and Research). Dr. Teng has a wide variety of expertise ranging from cellular and molecular biology to translational research, and his research projects are supported by DOD, NIH and other fund resources. Through his teamwork, Dr. Teng is striving to bridge multiple major research themes, tumor microenvironment, metabolism and metastasis, with an emphasis on several central regulators in cancer progression and treatment resistance (e.g. FGF19/FGFR4, ATAD3A, WASF3), and to develop novel promising diagnostic and therapeutic strategies (Nanoparticle-based drugs, stapled peptide inhibitors) by targeting them. His research outcome provides a balanced mix of basic and translational science, seeking to shift current research and clinical practice paradigm that will directly impact the future development of effective therapy for cancer patients.


Dr Vigil

Department of Hematology/Oncology and Stem cell Transplant, University of Iowa Holden Cancer Center, United States

Dr Vigil

Associate Editor: Dr. Carlos Vigil-Gonzales

Dr Vigil-Gonzales is an Assistant Professor of Medicine at University of Iowa Holden Cancer Center department of Hematology /Oncology and Stem Cell transplantation.

He received his MD at Universidad Peruana Cayetano Heredia and completed his post graduate education at University of Texas MD Anderson and Vanderbilt University in Tennessee in leukemia and stem cell transplant respectively. He is a translational and clinical cancer researcher focusing on especially on myeloid malignancies in relapsed and refractory settings.

He is member of several national and international societies in hematology malignancies and had served as committee member in several occasions.

Dr Vigil-Gonzales has been invited speaker in national and international conference , is author and co-author of multiple articles and abstracts published in prestigious journals such as Blood, Journal of Clinical Oncology and others. 


Professor Xu

Department of General Surgery, Zhongshan Hospital, Fudan University, China (PRC)

Professor Xu

Associate Editor: Professor Jianmin Xu

Dr. Jianmin Xu graduated from Shanghai Medical University in 1990 and was trained as an attending surgeon and specialist of general surgery from 1994 to 1999 at Zhongshan Hospital, Shanghai Medical University. In 1999, he received the Ph.D. degree in General Surgery from Shanghai Medical University. In 2001, he studied at Harvard Medical School and Massachusetts General Hospital, and in 2004, he studied at Hospital Ambroise Paré, Paris. He focuses on basic research and clinical treatment of colorectal cancer and liver metastasis, standardized treatment and minimally invasive operation of colorectal cancer, and Da Vinci robotic assisted colorectal surgery.

For the achievements of “Surgical and Comprehensive Treatment of Colorectal Liver Metastasis”, he has won the First Prize of Shanghai Medical Achievements (2011), the First Prize of Science and Technology Progress Award presented by the Ministry of Education (2011), and the First Prize of Shanghai Science and Technology Progress Award (2012). He was selected as one of Outstanding Academic Leaders of Shanghai Health System in 2011, and winner of Shanghai Outstanding Leading Talents in 2012.

Professor Xu is currently the Deputy Director of Department of General Surgery, Zhongshan Hospital, the Deputy Director of Center of Colorectal Cancer, Fudan University, the Chief of Multi-Disciplinary Team of Colorectal Cancer, Zhongshan Hospital, and the Deputy Director of Teaching and Research Section of Surgery, Zhongshan Hospital, Fudan University. He conducted several national projects, and served as an expert in organizations such as Colorectal Surgeon Committee of Chinese Medical Doctor Association. He has published a number of original and review articles, including publications as first and corresponding author in Annals of Surgery and Journal of Clinical Oncology. 


Dr Yamada

Surgery, University of Illinois, United States

Dr Yamada

Associate Editor: Dr Tohru Yamada

Dr. Tohru Yamada is an Assistant Professor in the Department of Surgery, Division of Surgical Oncology at the University of Illinois, College of Medicine. Dr. Yamada was a Post-Doctoral Fellow in the school’s Department of Microbiology & Immunology. He received his B.S., M.S. and Ph.D. in Biotechnology from Tokyo Institute of Technology, Japan. His research interests and expertise are the discovery and development of new class of peptide-based anticancer agents and carriers for imaging agent targeting cancers on the basis of molecular biology, protein/peptide chemistry, cell biology and cancer biology. Dr. Yamada is also Director, Drug Development of CDG Therapeutics, Inc., a clinical-stage biotechnology company (Chicago, IL) engaged in the development and commercialization of proprietary peptides derived from pathogenic and non-pathogenic bacteria and green plants. He holds ~25 issued and pending US and international patents, and has authored a number of original research/review/news articles featured in Nature Medicine, Nature Review Clinical Oncology, Science, Lancet Oncology etc. Dr. Yamada is currently a member of the Editorial Board of several peer-reviewed scientific journals such as International Journal of Nanomedicine.

 


Dr Yang

Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, United States

Dr Yang

Associate Editor: Dr Xuyu Yang

Dr.Yang is a research scientist at Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health. He obtained his Ph.D in XiangYa School of Medicine, Central South University, in the area of pathology and Pathophysiology. His research focus on the molecular mechanisms underlying tumor metastasis, and identification of new target for cancer gene therapy in pre-clinical and clinical evaluations.


Dr Yuzhalin

Molecular&Cellular Oncology, The University of Texas MD Anderson Cancer, United States

Dr Yuzhalin

Associate Editor: Arseniy Yuzhalin

Dr. Arseniy E. Yuzhalin obtained his bachelor's degree in Genetics at Kemerovo State University, Russia. His early studies under supervision of Prof. Elena Brusina were devoted to the investigation of the impact of gene polymorphisms on a risk of onset of diseases such as cancer and atherosclerosis. In 2012-2013 he worked at the Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russia as a junior researcher, where he explored the role of calcium-phosphate bions in eliciting endothelial dysfunction and development of atherosclerosis. In 2013 he joined the laboratory of Prof. Ruth Muschel at the Department of Oncology, University of Oxford, UK, where he earned his Master by Research and subsequently Doctor of Philosophy degrees. During this time he elucidated the influence of the extracellular matrix on the progression of colorectal cancer liver metastasis utilising high-throughput approaches such as quantitative proteomics. In 2018 he joined Dr. Anton Kutikhin lab at the Research Institute for Complex Issues of Cardiovascular Diseases as a lead research scientist to pursue his research interest in endothelial biology with relation to various pathophysiological conditions. He is also studying brain metastasis biology with Professor Dihua Yu lab at the The University of Texas MD Anderson Cancer Center, USA.


Dr Zhang

H. Lee Moffitt Cancer Center & Research Institute, United States

Dr Zhang

Associate Editor:  Dr. Ling Zhang

Dr. Ling Zhang is an Associate Member in the Department of Hematopathology and Laboratory Medicine, Director of the Hematopathology Fellowship Program, and Associate Professor, USF Oncologic Sciences. Dr. Ling Zhang obtained her MD and MS degree and completed her residency and fellowship in China. When she arrived in the United States in 1994 she worked as a Postdoctoral Fellow and Research Associate at MD Anderson Cancer Center. During working in the well-known cancer institute (1994-2001) she gained a great deal of research experience in cancer biology, immunology and therapeutic experiences. She then completed a residency in pathology and clinical medicine at the University of Louisville, Kentucky in 2005 followed by a two-year fellowship in hematopathology at Cedars-Sinai Medical Center in Los Angeles, California. She initially took a position as a Medical Associate Director in a commercial laboratory (U.S. Labs/LabCorp) in Irvine, California for one year, and came to Moffitt in June 2008 as an Assistant Member. During the first 4-5 years, she has exceeded the pre-set goals for clinical service, education and research and was appointed program director of the ACGME accredited hematopathology fellowship in 2011 and successfully promoted to the rank of Associate Member with Tenure in 2013. Dr. Zhang is an outstanding and dedicated clinician educator who continues to take an active role in clinical translational research, utilizing her skills as a hematopathologist along with her knowledge of immunohistochemistry and molecular diagnostics to bring value to both basic science investigations and clinical trials, which were evident by over 20 translational research projects that she proposed (as principle investigator) or has been involved (as co-PI), of which several are industry, state or nationally sponsored. In addition, her experts in diagnosis of myelodysplastic syndromes as well as other myeloid neoplasms made her grow and become one of the key faculty members in multiple phase I-III clinical trials during the past years. She currently has effort as an investigator on the NIHBI National MDS Study, where she oversees the national MDS Tissue Repository and aim to explore potential mechanisms of MDS and its related precursor neoplasms. She has been the Director of the Hematopathology fellowship program and has successfully overseen extended ACGME accreditation and the successful matriculation of each of our fellows. She is an excellent mentor and is sought by fellows and residents for clinical research activities and awarded outstanding clinical faculty by USF in 2013. Several fellows she mentored have received awards issued by institution or national society, e.g., AOA. She has also been highly productive in publishing, and has gained an international reputation, being asked to present diagnostically challenging cases at international workshops. She has also been involved in editions of books and contributed >10 book chapters to expert edited books in the field.


Editorial Board

Professor Josep M. Argiles, Department of Biochemistry and Biomedicine, University of Barcelona, Barcelona, Spain

Rolf F. Barth, M.D, Academy Professor, Department of Pathology, The Ohio State University, Columbus, Ohio

Yiwen Bu, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA

Fung-Lung Chung, Professor, Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA

Jean-Luc Coll, Director of Research, Institute for Advanced Biosciences, La Tronche, France

George Ding, Department of Radiation Oncology, Biomedical Research Education & Training, Vanderbilt University Medical Center, Nashville, TN, USA

Raju Kandimalla, PhD, Research Associate, Baylor Scott&White Research Institute and Charles A. Sammons Cancer Center, Center for Gastrointestinal Research &, Center for Translational Genomics and Oncology, Texas, USA.

Saad Khan, Hematology and Oncology, UT Southwestern Medical Center in Dallas Texas, USA

Muthusamy Kunnimalaiyaan, Assistant Professor, Department of Surgery, Tulane University-School of Medicine, New Orleans, USA.

Axel S. Merseburger, Professor and Chairman of the Department of Urology, University Hospital Schleswig-Holstein, Germany

Shakeel Modak, Member and Attending, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, USA

Gianmaria Pennelli, MD, Assistant Professor in Pathology, Department of Medicine (DIMED), University of Padova, Italy.

Dr Rituraj Purohit, Senior Scientist at CSIR-Institute of Himalayan Bioresource Technology, Palampur, India.

James A Radosevich, Professor, Experimental Pathology, Center for Molecular Biology of Oral Diseases, College of Dentistry, University of Illinois at Chicago, IL, USA

Prof. Dr. Jean Rommelaere, Professor in Tumor Virology, Department of Infection, Inflammation and Cancer, German Cancer Research Center, Heidelberg, Baden-Württemberg, Germany

Stefania Staibano, Professor in Pathology, Department of Advanced Biomedical Sciences, University Federico II of Naples, Naples, Italy

Nurdan Tacyildiz, Professor, Medical School, Department of Pediatric Oncology, Ankara University, Ankara, Turkey

Guang-Hong Tan, Dr, Hainan Provincial Key Laboratory of Tropical Medicine, Hainan Medical College, Xueyuan Lu, Haikou, Hainan, People's Republic of China

Dinesh Vyas, Chair, Department of Surgery, College of Medicine, California NS University, USA

Ping Wang, Assistant Professor, Department of Radiology, Precision Health Program, College of Human Medicine, Michigan State University, East Lansing, MI, USA